Stoke Therapeutics 過去の業績
過去 基準チェック /06
Stoke Therapeutics's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 65.9% per year.
主要情報
-25.3%
収益成長率
12.5%
EPS成長率
Biotechs 業界の成長 | 17.0% |
収益成長率 | 65.9% |
株主資本利益率 | -42.7% |
ネット・マージン | -683.3% |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
Dec 14収支内訳
Stoke Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 15 | -104 | 44 | 86 |
31 Mar 24 | 8 | -109 | 41 | 85 |
31 Dec 23 | 9 | -105 | 41 | 82 |
30 Sep 23 | 9 | -103 | 40 | 82 |
30 Jun 23 | 9 | -105 | 40 | 81 |
31 Mar 23 | 15 | -99 | 40 | 79 |
31 Dec 22 | 12 | -101 | 39 | 78 |
30 Sep 22 | 9 | -100 | 38 | 73 |
30 Jun 22 | 6 | -96 | 37 | 67 |
31 Mar 22 | 3 | -94 | 34 | 63 |
31 Dec 21 | 0 | -86 | 32 | 54 |
30 Sep 21 | 0 | -76 | 29 | 47 |
30 Jun 21 | 0 | -67 | 26 | 41 |
31 Mar 21 | 0 | -58 | 23 | 35 |
31 Dec 20 | 0 | -52 | 21 | 32 |
30 Sep 20 | 0 | -48 | 19 | 30 |
30 Jun 20 | 0 | -43 | 17 | 29 |
31 Mar 20 | 0 | -38 | 14 | 27 |
31 Dec 19 | 0 | -32 | 12 | 24 |
30 Sep 19 | 0 | -26 | 9 | 20 |
30 Jun 19 | 0 | -21 | 7 | 15 |
31 Mar 19 | 0 | -16 | 6 | 11 |
31 Dec 18 | 0 | -13 | 4 | 8 |
質の高い収益: STOK is currently unprofitable.
利益率の向上: STOK is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: STOK is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
成長の加速: Unable to compare STOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: STOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
株主資本利益率
高いROE: STOK has a negative Return on Equity (-42.67%), as it is currently unprofitable.